Literature DB >> 10199394

The structural basis for DNA binding by an anti-DNA autoantibody.

Y J Jang1, D Sanford, H Y Chung, S Y Baek, B D Stollar.   

Abstract

We have used single and multiple site-directed mutagenesis, and molecular modeling, to identify critical residues in the DNA binding site of MAb 2C10, an IgG anti-dsDNA autoantibody from an MRL/lpr lupus mouse. Simultaneous replacement of four Arg residues in the CDR3H abolished binding activity. With one exception, replacement of any one of these Arg residues reduced the activity to 20-50% of the unmutated scFv activity. Arg to Asp replacements had a slightly greater effect than Arg to Ala replacements. In the one exceptional case, replacement of Arg99 with Ala actually increased DNA binding five-fold and replacement by Asp had little effect. Mutation of Phe32 and Asn35 to A1a in CDRIH decreased DNA binding, whereas replacement of Arg31 with A1a had negligible effect. Ala substitution of any one of a cluster of Asp residues in CDR1L increased DNA binding three to six-fold, confirming previous findings that the L-chain of MAb 2C10 is not favorable for DNA binding. The L-chain does participate in shaping the selectivity of antigen binding, and mutation of CDR3L residue Asp92 or Asn93 caused a decrease in DNA binding activity. Directed mutagenesis, consistent with a molecular model, indicates that: several CDR amino acids contribute to DNA binding, without one residue dominating; both VH and VL CDR3 domains contribute to specificity of binding whereas the CDR1L hinders DNA binding. The results suggest a significant role for electrostatics in the interaction of DNA with MAb 2C10.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 10199394     DOI: 10.1016/s0161-5890(98)00095-9

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  9 in total

1.  The Entamoeba histolytica mitochondrion-derived organelle (crypton) contains double-stranded DNA and appears to be bound by a double membrane.

Authors:  S Ghosh; J Field; R Rogers; M Hickman; J Samuelson
Journal:  Infect Immun       Date:  2000-07       Impact factor: 3.441

2.  Specific recognition of a dsDNA sequence motif by an immunoglobulin VH homodimer.

Authors:  Hulin Jin; Jorge Sepúlveda; Oscar R Burrone
Journal:  Protein Sci       Date:  2004-12       Impact factor: 6.725

3.  Autoreactivity in human IgG+ memory B cells.

Authors:  Thomas Tiller; Makoto Tsuiji; Sergey Yurasov; Klara Velinzon; Michel C Nussenzweig; Hedda Wardemann
Journal:  Immunity       Date:  2007-02       Impact factor: 31.745

4.  Somatic hypermutation as a generator of antinuclear antibodies in a murine model of systemic autoimmunity.

Authors:  Wenzhong Guo; Diana Smith; Katja Aviszus; Thiago Detanico; Ryan A Heiser; Lawrence J Wysocki
Journal:  J Exp Med       Date:  2010-08-30       Impact factor: 14.307

5.  The effect of polyamines on the binding of anti-DNA antibodies from patients with SLE and normal human subjects.

Authors:  Xiao Wang; Nancy A Stearns; Xingfu Li; David S Pisetsky
Journal:  Clin Immunol       Date:  2014-04-13       Impact factor: 3.969

6.  Light chain editing generates polyreactive antibodies in chronic graft-versus-host reaction.

Authors:  Esther J Witsch; Hong Cao; Hidehiro Fukuyama; Martin Weigert
Journal:  J Exp Med       Date:  2006-06-26       Impact factor: 14.307

7.  Functional Versatility of AGY Serine Codons in Immunoglobulin Variable Region Genes.

Authors:  Thiago Detanico; Matthew Phillips; Lawrence J Wysocki
Journal:  Front Immunol       Date:  2016-11-22       Impact factor: 7.561

Review 8.  The dsDNA, Anti-dsDNA Antibody, and Lupus Nephritis: What We Agree on, What Must Be Done, and What the Best Strategy Forward Could Be.

Authors:  Ole Petter Rekvig
Journal:  Front Immunol       Date:  2019-05-15       Impact factor: 7.561

9.  Light chain editors of anti-DNA receptors in human B cells.

Authors:  Olga Kalinina; Yue Wang; Kevin Sia; Marko Radic; Pierre-André Cazenave; Martin Weigert
Journal:  J Exp Med       Date:  2014-01-27       Impact factor: 14.307

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.